Biotech Press Releases

BullFrog AI Holdings, Inc. (N A S D A Q: BFRG) $BFRG Published Whitepaper Titled "AI in Bioinformatics: Turning Complex Data into Actionable Insights with BullFrog Data Networks®"

VSee Health, Inc. (N A S D A Q: VSEE) $VSEE Reported Q3 Revenues Reach $3.98 Million, Up 19% Year-Over-Year with Clients Including NASA, U.S. Department of Health and Human Services, McKesson, DaVita and The Nation of Qatar

NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP) NRXP Also Reports Its Superior Preservative-Free IV Ketamine Now Submitted for FDA Abbreviated New Drug Application

OKAVA Pharmaceuticals is a clinical-stage company developing medicines to enable dogs and cats to live longer, healthier lives.

NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP) $NRXP; $750 Million Market for Suicidal Depression Market Awaits

$NRXP Has Manufactured Multiple Commercial Lots of NRX-100 and KETAFREE™ with a Shelf Life of Three Years.

Analyst D. Boral Targets NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP) $NRXP at $34 Per Share — Pioneering Breakthroughs in Treatment-Resistant Depression and Chronic Pain

H.C. Wainwright Initiates Coverage with $34 Price Target, Citing Paradigm Shift in Depression Treatment. NRx Pharmaceuticals (N A S D A Q: NRXP) $NRXP

BullFrog AI Holdings, Inc. (N A S D A Q: BFRG) $BFRG Published Whitepaper Titled "AI in Bioinformatics: Turning Complex Data into Actionable Insights with BullFrog Data Networks®"

VSee Health, Inc. (N A S D A Q: VSEE) $VSEE Reported Q3 Revenues Reach $3.98 Million, Up 19% Year-Over-Year with Clients Including NASA, U.S. Department of Health and Human Services, McKesson, DaVita and The Nation of Qatar

NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP) NRXP Also Reports Its Superior Preservative-Free IV Ketamine Now Submitted for FDA Abbreviated New Drug Application

OKAVA Pharmaceuticals is a clinical-stage company developing medicines to enable dogs and cats to live longer, healthier lives.

NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP) $NRXP; $750 Million Market for Suicidal Depression Market Awaits

Learn how surface plasmon resonance service provides accurate kinetic data for drug discovery and molecular interaction studies.

$NRXP Has Manufactured Multiple Commercial Lots of NRX-100 and KETAFREE™ with a Shelf Life of Three Years.

MyAmici, a leading provider of LabOps solutions for biotech and life science organizations, is pleased to announce its strategic entry into the Swiss market through a partnership with Kisco Pharma Outsourcing Solutions.

Analyst D. Boral Targets NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP) $NRXP at $34 Per Share — Pioneering Breakthroughs in Treatment-Resistant Depression and Chronic Pain

H.C. Wainwright Initiates Coverage with $34 Price Target, Citing Paradigm Shift in Depression Treatment. NRx Pharmaceuticals (N A S D A Q: NRXP) $NRXP

Founder of 360Disruption leads cross-border FDI and healthtech ventures aligned with UAE Vision 2031 and GCC Vision frameworks.

As therapeutic antibodies continue to reshape modern medicine, one challenge remains at the core of successful drug development — minimizing immune reactions while preserving antibody function.

Program to Advance Next-Generation Legumain-Cleavable ADC Platform for Advanced Cancers

Caroline Briggs, CEO of Amici, has been named winner of The Disruptor Award in The LDC Top 50 Most Ambitious Business Leaders programme for 2025.

ABCDx SA, a leader in biomarker-based diagnostics for acute brain disorders, today announced two strategic milestones strengthening its competitive position and licensing opportunities: The USPTO has granted ABCDx a patent protecting its novel H-FABP +...

NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP) $NRXP Refiles Abbreviated New Drug Application; $40 Price Target in New H. C. Wainright Research Report

NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP) $NRXP Suitability Petition is required for shift from multidose packaging of ketamine to single-patient dose preservative free ketamine

WorldUpstart proudly announces the launch of its Fall 2025 U.S. Market Gateway Accelerator, featuring a dynamic cohort of international Life Science and MedTech companies.

NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP) $NRXP Continues Expansion with Completion of Dura Medical Acquisition in Network of Interventional Psychiatry Clinics

NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP) $NRXP Sees 10-Fold Market Expansion to 13 Million Americans for Bipolar Depression Alone.

NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP) $NRXP Has $7.8 Million for Clinic Acquisitions and Purchase of Kadima Neuropsychiatry Institute as Treatment Model and Leading Investigative Site for Suicidal Depression / PTSD

NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP) $NRXP Has $7.8 Million for Clinic Acquisitions and Purchase of Kadima Neuropsychiatry Institute as Treatment Model and Leading Investigative Site for Suicidal Depression / PTSD

NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP) $NRXP Has $7.8 Million for Clinic Acquisitions, Purchase of Kadima Neuropsychiatry Institute as Treatment Model and Leading Investigative Site for Suicidal Depression / PTSD

Life Sciences Investor Brings Personal Mission to Discussion on Building LA's Biomanufacturing Ecosystem

Renovaro, Inc. (N A S D A Q: RENB) $RENB Also Receives U.S. Patent to Strengthen AI-Driven Drug Discovery and Diagnostics Platform

VSee Health (N A S D A Q: VSEE) $VSEE Major Clients Include NASA, U.S. Department of Health and Human Services, McKesson, DaVita and the Entire Nation of Qatar

NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP) $NRXP Has $7.8 Million for Clinic Acquisitions and Purchase of Kadima Neuropsychiatry Institute as Treatment Model and Leading Investigative Site for Suicidal Depression / PTSD

Expert Guidance to Help Biotechs Scale Smartly, From Funding to Exit

NRx Pharmaceuticals, Inc. (Stock Symbol: NRXP) $NRXP Has $7.8 Million in Financing for Clinic Acquisitions and Purchase of Kadima Neuropsychiatry Institute as Treatment Model and Leading Investigative Site for Suicidal Depression / PTSD

$NRXP Closing $7.8 Million in Financing for Clinic Acquisitions and Purchase of Kadima Neuropsychiatry Institute Treatment Model and Leading Investigative Site

$NRXP NRx Pharmaceuticals, Inc. (Stock Symbol: NRXP): Set Up for $300 Million in Milestones on Tiered Double-Digit Royalties